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Abbreviations 
BOS= Bronchiolitis Obliterans Syndrome 
GORD= Gastro-Oesophageal Reflux Disease 
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Abstract:  
Long-term survival post lung tranpslant, is reduced significantly by Bronchiolitis 
Obliterans Syndrome. It is suggested that extra-oesophageal reflux disease is a risk 
factor for Bronchiolitis Obliterans Syndrome and that anti-reflux surgery may be 
beneficial. Practice between centres varies greatly, however. We suggest a need for  
improved evidence and standardisation. 
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Mini-review 
 
This mini-review aims to highlight the discrepancies in anti-reflux surgery in the lung 
transplantation population and make a call for standardisation of approaches to 
therapy and improved evidence of their effects.  
Lung transplantation is an accepted treatment strategy for end-stage lung disease but s 
urvival of lung allograft recipients is significantly lower than other organ transplant 
recipients. This may be due to the unique environment to which the lungs are exposed 
and as a result five year survival post-transplantation is 60%(1).  The 
pathophysiological process of chronic rejection is Obliterans Bronchiolitis, 
characterised by progressive fibrosis of the small airways, leading to airway 
obstruction. This manifests clinically as Bronchiolitis Obliterans Syndrome(BOS)(1). 
  
Traditionally, BOS was thought to be caused by cumulative alloimmune injuries but 
there has been no significant impact on BOS over the last twenty years, despite the 
use of novel immunosuppressive strategies(1, 2). One current hypothesis is a link with 
gastro-oesophageal refux disease (GORD)(1). There is no doubt that GORD post-lung 
transplantation is common with up to 75% of patients having demonstrable reflux 
based on pH studies. Causative factors may include intra-operative vagal damage, an 
impaired cough and airway mucociliary clearance, an immunosuppression drug effect 
or the pre-existing presence of GORD(1, 2). However the link with BOS is yet to be 
validated even in animal models. A recent paper has suggested that macroaspiration 
of gastric fluid to be injurious in a rat model of lung-transplantation, but the pattern of 
injury described is a pan-lung injury, perhaps not truely OB, and more akin to Acute 
Lung Injury, which is believed to be caused by a large volume gastric aspiration. No 
animals studies have been performed looking at the effects of chronic microaspiration 
which is thought to occur in the clinical setting, nor the effects of gastro-duodenal 
aspiration versus gastric aspiration.   
 
However clinical research does suggest an association between reflux and BOS. In a 
study of 43 patients undergoing pH measurements at a median of 558 days post-
transplant, 76% of patients with abnormal lung function had abnormal oesophageal 
pH compared to 59% of patients without allograft dysfunction having an abnormal pH 
study. A negative correlation existed between the severity of total/upright acid reflux 
and FEV1 ratio (r= -0.341; p=0.025)(3).  
 
If GORD and BOS are linked, then prophylactic treatment using proton pump 
inhibitors to reduce gastric acid production should have an impact on outcome. These 
have not been shown to be effective in preventing weakly acidic reflux or aspiration 
in clinical studies. This suggests PPI therapy will not prevent reflux/aspiration but this 
is not widely understood and it is a common misunderstanding that PPIs may stop 
reflux(4, 5). Although intra-operative vagal damage is associated with a poor cough 
reflex, recent evidence suggests that the cough response improves in the first year 
post-transplant(6). This should protect against aspiration and the development of 
BOS. In contrast, azithromycin (a macrolide antibiotic) with promotility properties 
improves airflow limitation post-transplant even in patients with longstanding BOS 
could this effect be linked to an amelioration of GORD? 
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Nevertheless, recent studies have demonstrated a survival benefit and delayed onset of 
BOS when anti-reflux surgery is performed, particularly with early intervention(2, 7). 
The laparoscopic approach is now the procedure of choice with successful long-term 
control of reflux. Anti-reflux surgery was first shown as being both safe to perform 
and beneficial in lung transplant recipients in 2003.  Davis et al. demonstrated over 
80% of 43 patients who underwent anti-reflux surgery post-lung transplantation had a 
significant increase in FEV1- mean improvement 24% post-fundoplication. The more 
advanced the BOS, the less improvement gained(2). In a follow up to this study  
(n=76), survival was significantly better for patients who underwent an early 
(<90days) versus a late fundoplication. This was most pronounced at 3 years (100% 
versus 69-86%; p=0.03). This early fundoplication survival effect was also noted even 
when compared to patients with a “normal” pH study. The “normal” patient group 
included those with mild acidic reflux with an mean acid exposure (7.9%) above the 
normal limits. This may explain the unexpected finding of a beneficial effect of early 
antireflux surgery over patients with a “normal” pH study.   The most recent data 
published in abstract form (8) suggests that early fundoplication reduces BOS but 
does not show an improved survival at one year. However, this follow up is limited.  
  
There are significant limitations to this evidence, the available studies involve small 
numbers, have limited follow up, much of the evidence is retrospective and derived 
from a single centre(2, 7). Methodological problems make it difficult to draw robust 
conclusions.   
 
 
 
We have therefore reviewed the published literature and contacted transplant centres 
in Europe, North America and Australia, to identify if there was a consensus 
regarding investigation of reflux and indications for intervention. The essential 
finding of this exercise was that there is none. There are numerous ways to detect 
reflux, which is assumed to be a prerequisite for aspiration. Oesophageal pH 
monitoring is the most traditional modality, but this assumes all reflux episodes are 
acid related(9). In addition assessing for reflux by pH monitoring may not be the best 
approach as for aspiration to occur the refluxate needs to pass through the proximal 
oesophagus and enter the pharynx. The Bilitec monitor has been used to detect bile-
containing refluxate but has limitations. As a result, pH/impedance is now the 
recognised standard assessment tool, as it can detect episodes of non-acid reflux, 
which definitely occurs in lung transplant recipients and which is associated with 
aspiration(4). Similarly bronchoalveolar lavage (BAL) specimens can be analysed for 
the presence of aspiration biomarkers such as pepsin and bile salts, the latter 
suggestive of duodeno-gastro-oesophageal reflux(1, 4, 5). Our unit has demonstrated 
that pepsin in BAL samples is increased in lung transplant recipients and is associated 
with acute rejection(5). Bile salts are cytotoxic and the presence of bile salts in BAL 
specimens has been associated with an early onset of BOS(1, 4). It has been suggested 
that such biomarker approaches may be used as an indication for fundoplication. 
However assay variability and differing detection limits are serious problems and the 
available literature does not take this into account(10). Further work is needed to 
standardise and validate these assays. As a result, the indications for fundoplication 
based on the biochemical detection of aspiration are contentious.  
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Little is known about what happens to reflux over the first year post-transplant and 
there is no consensus about when to assess for reflux or if reflux is demonstrated 
when an anti-reflux procedure would be indicated. One paper has suggested that pre-
transplant fundoplication should be performed in all “fit” patients who have 
demonstrable reflux(11). There are potential benefits in performing fundoplication 
pre-transplant, not least offering immediate protection from micro-aspiration and lung 
injury. There have been isolated reports of a normalisation in lung function in several 
patients and withdrawal from  transplantation lists(12). However the risks of surgery 
are higher in this population and there is potentially no benefit, as several patients 
have died pre-transplantation.  
 
In summary, there is growing interest in the role of extra-oesophageal reflux in BOS 
and the potential benefits of fundoplication in well-characterised patients. Most units 
state an advocacy for some form of anti-reflux surgery in either patients with 
demonstrable reflux or more pragmatically, in symptomatic patients with reflux. 
However, there is no consensus between centres. Based on the premise that surgery 
benefits those with reflux and biomarker evidence of aspiration or patients with 
deteriorating lung function, the major units are recognising the case for creating more 
solid guidelines. We propose that this is a priority since current evidence may suggest 
a benefit with early surgery and little benefit for surgery in more advanced disease. 
This area of investigation and treatment is in its infancy and would benefit from 
appropriate leadership, through national and international societies. The next steps 
should be standardisation of biomarker assays and surgical practice. This may then 
allow appropriate trials.  
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